Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Tissue Transplantation01:24

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel (Brexu-cel) in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA).

Transplantation and cellular therapy·2026
Same author

Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL.

Blood advances·2026
Same author

Outpatient Versus Inpatient Axicabtagene Ciloleucel CAR T-Cell Therapy in Non-Hodgkin's Lymphoma: Insights From A US Multicenter Transplant and Cellular Therapy Network.

Transplantation and cellular therapy·2026
Same author

Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL.

Blood·2026
Same author

Acute Toxicities of Bone Marrow Donation in Unrelated Donors with Sickle Cell Trait: A Center for International Blood and Marrow Transplantation Research Analysis.

Transplantation and cellular therapy·2025
Same author

CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia.

Blood advances·2025
Same journal

Embedding cardiovascular risk assessment into routine BTK inhibitor management in chronic lymphocytic leukemia.

Expert review of hematology·2026
Same journal

The impact of a cancer diagnosis for myeloproliferative neoplasm (MPN) patients.

Expert review of hematology·2026
Same journal

Lessons from warfarin management during the COVID-19 pandemic: from crisis to an opportunity to revolutionize telemedicine for chronic disease care.

Expert review of hematology·2026
Same journal

Efficacy of pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis: a matching-adjusted indirect treatment comparison.

Expert review of hematology·2026
Same journal

Prognostic factors for patients with relapsed or refractory multiple myeloma who are initiating a fourth or later line car T-cell or bispecific antibody therapy: a systematic literature review and meta-analysis.

Expert review of hematology·2026
Same journal

The emerging and evolving role of flow cytometry in myelodysplastic syndrome diagnosis.

Expert review of hematology·2026
See all related articles

Related Experiment Video

Updated: Jun 6, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Relapse after allogeneic stem cell transplantation.

A John Barrett1, Minoo Battiwalla

  • 1CRC Building 10 Room 3-5322, 10 Center Drive, MSC 1202, Bethesda, MD 20892-1202, USA. barrettj@nhlbi.nih.gov

Expert Review of Hematology
|November 19, 2010
PubMed
Summary
This summary is machine-generated.

Allogeneic stem cell transplantation (SCT) can fail, leading to relapse in high-risk cancers. Prognosis after relapse depends on timing, disease type, and transplant factors, guiding salvage therapy options.

More Related Videos

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice
03:40

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Related Experiment Videos

Last Updated: Jun 6, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice
03:40

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Allogeneic stem cell transplantation (SCT) is a curative therapy for high-risk malignancies.
  • Relapse after SCT presents limited salvage treatment options.

Purpose of the Study:

  • To review prognostic factors for hematological malignancies relapsed after SCT.
  • To outline salvage treatment strategies for post-SCT relapse.

Main Methods:

  • Review of prognostic factors influencing outcomes in relapsed hematological malignancies post-SCT.
  • Analysis of treatment modalities including modified SCT, chemotherapy, targeted therapy, and immunotherapy.

Main Results:

  • Prognosis is determined by time to relapse (≤6 months is worst), disease type (chronic leukemias/lymphomas offer better prognosis), disease burden/site, and first transplant conditions.
  • Favorable transplant conditions allow for enhanced alloimmune or antileukemia effects.

Conclusions:

  • Salvage therapy decisions are guided by prognostic factors.
  • Treatment options range from modified SCT to chemotherapy, targeted agents, immunotherapy, or palliative care.